(NASDAQ: ASND) Ascendis Pharma A's forecast annual revenue growth rate of 44.4% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Ascendis Pharma A's revenue in 2026 is $847,214,117.On average, 18 Wall Street analysts forecast ASND's revenue for 2026 to be $87,528,324,912, with the lowest ASND revenue forecast at $71,937,725,664, and the highest ASND revenue forecast at $98,392,640,136. On average, 18 Wall Street analysts forecast ASND's revenue for 2027 to be $125,277,216,792, with the lowest ASND revenue forecast at $99,374,725,128, and the highest ASND revenue forecast at $152,652,835,944.
In 2028, ASND is forecast to generate $154,923,907,488 in revenue, with the lowest revenue forecast at $119,323,326,528 and the highest revenue forecast at $181,747,103,832.